Intravenous Lidocaine: Old-School Drug, New Purpose—Reduction of Intractable Pain in Patients with Chemotherapy Induced Peripheral Neuropathy
Table 3
PPTs and associated NRS scores before and after treatment with iv lidocaine.
Location
Before
After
Effect
-statistic
95% CI
value
PPT
M. trapezius pars medialis
51.7 ± 14.3
52.0 ± 12.5
0.34
−0.086
[−9.6; 8.9]
1
Thenar eminence
58.0 ± 18.2
58.3 ± 14.9
0.33
−0.070
[−11.4; 10.7]
1
M. rectus femoris
71.3 ± 26.4
69.0 ± 16.2
−2.31
0.257
[−18.5; 23.1]
1
M. abductor hallucis
55.6 ± 27.7
56.8 ± 18.3
1.16
−0.192
[−15.0; 12.7]
1
NRS
M. trapezius pars medialis
5.6 ± 2.0
5.4 ± 2.4
−0.11
0.187
[−1.3; 1.5]
1
Thenar eminence
5.6 ± 1.9
5.1 ± 1.8
−0.56
2.294
[−0.0; 1.1]
0.204
M. rectus femoris
4.9 ± 2.3
5.0 ± 2.0
0.06
−0.127
[−1.1; 1.0]
1
M. abductor hallucis
6.3 ± 2.0
5.7 ± 2.0
−0.67
1.193
[−0.6; 2.0]
1
PPT: pressure pain threshold, N/cm2; NRS: numeric rating scale, scale 0–10. Data are expressed as means ± SD; Bonferroni-corrected values are reported.
